Literature DB >> 28657350

Bispectral index as a predictor of unsalvageable traumatic brain injury.

Saeed Mahmood1, Ayman El-Menyar2,3, Amr Shabana1, Ismail Mahmood1, Mohammad Asim2, Husham Abdelrahman1, Hassan Al-Thani1.   

Abstract

PRIMARY
OBJECTIVE: We aimed to assess the utility of bispectral index (BIS) monitoring to diagnose brain death (BD) in patients with severe traumatic brain injury (TBI). RESEARCH DESIGN AND METHODS: A prospective observational study was conducted for patients with severe TBI between 2012 and 2014. MAIN OUTCOMES AND
RESULTS: This study included 62 patients with a mean age of 32.5 ± 10.5 years. Nine patients had BD on admission with a sustainable BIS value of 0. Fifty-three patients were not initially diagnosed with BD with BIS values of 2-56. Forty-four patients deteriorated to BD, and their respective BIS values progressively decreased to 0. Nine patients with mean BIS of 39.2 ± 9.0 recovered and were transferred to a specialized high dependency unit. BIS values showed positive correlation with the Glasgow Coma Score (GCS) on admission (r = 0.43, p = 0.001). Survivors had higher BIS values than those who were initially declared BD or those who died during the hospitalization course (p = 0.001).
CONCLUSION: BIS values have a significant correlation with initial GCS and can assist in the early detection of BD in patients with severe acute TBI. Further larger studies are needed to support our findings.

Entities:  

Keywords:  Bispectral index; brain death; outcome; severe coma; traumatic brain injury

Mesh:

Year:  2017        PMID: 28657350     DOI: 10.1080/02699052.2017.1330966

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  1 in total

1.  Use of propofol for prevention of post-delivery nausea during cesarean section: a double-blind, randomized, placebo-controlled trial.

Authors:  Kun Niu; Hui Liu; Ruo-Wen Chen; Qi-Wu Fang; Hui Wen; Su-Mei Guo; John P Williams; Jian-Xiong An
Journal:  J Anesth       Date:  2018-09-12       Impact factor: 2.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.